TScan Therapeutics Inc (TCRX) FinancialsTCRXTScan Therapeutics Inc

Evaluating the bottom line, TScan Therapeutics Inc maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -2901.33%, while the net margin is -2888.58%. These profitability ratios, combined with a Return on Equity (ROE) of -95.80%, provide a clear picture of how effectively TCRX converts its operational activities into shareholder value.

In the context of the broader market, TCRX competes directly with industry leaders such as MCRB and TIL. With a market capitalization of $52.79M, it holds a leading position in the sector. When comparing efficiency, TCRX's gross margin of 100.00% stands against MCRB's 100.00% and TIL's N/A. Such benchmarking helps identify whether TScan Therapeutics Inc is trading at a premium or discount relative to its financial performance.

TScan reported a revenue of $1.1 million in Q2 2026, down from $3.1 million in Q2 2025, indicating a significant decline in sales. The gross margin remains strong at 100%, but the company continues to report substantial net losses, with a net income of -$30.36 million in Q2 2026.